1. Long-Term Time in Target Range for Systolic Blood Pressure Since Childhood and Midlife Arterial Stiffness.
- Author
-
Wang Y, Qi H, Jia H, Wang D, Sun Y, Zhang BW, Du MF, Hu GL, Man ZY, Chu C, Yang XJ, Zhang T, Guo TS, Zhang X, Yan Y, Liu Z, Chang MK, Li H, Chen FY, Kang YM, Ren J, Yuan ZY, Zhang L, and Mu JJ
- Abstract
Background: Elevated blood pressure (BP) in childhood is associated with adult hypertension and arterial stiffness. However, the effect of long-term time in target range (TTR) for BP since childhood on the risk of arterial stiffness in midlife remains unclear., Objectives: The purpose of this study was to determine the independent association of TTR for systolic blood pressure (SBP) from childhood to midlife with arterial stiffness in adulthood., Methods: This study used data from the ongoing cohort of the Hanzhong Adolescent Hypertension Study. SBP-TTR was assessed over 36 years, with the target ranges of SBP defined as the 90th to 95th percentile of SBP for age, sex, and height in childhood, and 110 to 130 mm Hg in adulthood. Arterial stiffness was defined as brachial-ankle pulse wave velocity >1,400 cm/s., Results: Of the total 1,959 participants, 55.5% (1,088 of 1,959) were men, and the mean age was 49 years. The risk of arterial stiffness exhibited a gradual decrease with increasing SBP-TTR over the 36-year follow-up. Compared with the participants in the lowest quartile of SBP-TTR from childhood to midlife, those in the highest quartile showed significantly reduced arterial stiffness risk in midlife. This association persisted even after adjusting for mean SBP and SBP variability. Furthermore, men in the highest quartile of SBP-TTR demonstrated a markedly lower arterial stiffness risk than those in the lowest quartile, whereas this effect was not observed in women., Conclusions: Higher long-term SBP-TTR from childhood to midlife is associated with a reduced risk of arterial stiffness in midlife, regardless of the mean SBP or SBP variability., Competing Interests: This work was financially supported by the Science and Technology Innovation 2030-“Cancer, Cardiovascular and Cerebrovascular, Respiratory and Metabolic Diseases Prevention and Treatment Research” Major Project (2023ZD0503900, 2023ZD0503901); National Natural Science Foundation of China No. 82470457 (to Dr Yang Wang), 82070437 (to Dr Mu), and 82070549 (to Dr Li); the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University of China (No. XJTU1AFCRF-2022-002, XJTU1AF-CRF-2023-004, and XJTU1AF-CRF-2024-003); Xi'an Science and Technology Program Project (24YXYJ0141); Fundamental Research Funds for the Central Universities (No. xzy012023113); the Key R&D Projects in Shaanxi Province (No. 2023-ZDLSF-50); and the International Joint Research Center for Cardiovascular Precision Medicine of Shaanxi Province (2020GHJD-14). The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2025 The Authors.)
- Published
- 2025
- Full Text
- View/download PDF